RU2559570C2 - Композиции без приона на основе наночастиц и способы их получения - Google Patents
Композиции без приона на основе наночастиц и способы их получения Download PDFInfo
- Publication number
- RU2559570C2 RU2559570C2 RU2011146132/15A RU2011146132A RU2559570C2 RU 2559570 C2 RU2559570 C2 RU 2559570C2 RU 2011146132/15 A RU2011146132/15 A RU 2011146132/15A RU 2011146132 A RU2011146132 A RU 2011146132A RU 2559570 C2 RU2559570 C2 RU 2559570C2
- Authority
- RU
- Russia
- Prior art keywords
- albumin
- composition
- prion
- seq
- ligand
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A61K38/385—Serum albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2828—Prion diseases
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S210/00—Liquid purification or separation
- Y10S210/902—Materials removed
- Y10S210/903—Nitrogenous
- Y10S210/905—Protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Optics & Photonics (AREA)
- Inorganic Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16966509P | 2009-04-15 | 2009-04-15 | |
US61/169,665 | 2009-04-15 | ||
US23805209P | 2009-08-28 | 2009-08-28 | |
US61/238,052 | 2009-08-28 | ||
PCT/US2010/031197 WO2010121000A1 (en) | 2009-04-15 | 2010-04-15 | Prion-free nanoparticle compositions and methods |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2011146132A RU2011146132A (ru) | 2013-05-20 |
RU2559570C2 true RU2559570C2 (ru) | 2015-08-10 |
Family
ID=42982852
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2011146132/15A RU2559570C2 (ru) | 2009-04-15 | 2010-04-15 | Композиции без приона на основе наночастиц и способы их получения |
Country Status (25)
Country | Link |
---|---|
US (3) | US20100297243A1 (ja) |
EP (2) | EP3626233A1 (ja) |
JP (3) | JP5781500B2 (ja) |
KR (1) | KR20120044279A (ja) |
CN (1) | CN102460167B (ja) |
AU (1) | AU2010236382B2 (ja) |
BR (1) | BRPI1012525A2 (ja) |
CA (1) | CA2758913A1 (ja) |
CY (1) | CY1122617T1 (ja) |
DK (1) | DK2419732T3 (ja) |
ES (1) | ES2764100T3 (ja) |
HR (1) | HRP20192259T1 (ja) |
HU (1) | HUE047376T2 (ja) |
IL (1) | IL215765A (ja) |
LT (1) | LT2419732T (ja) |
ME (1) | ME03596B (ja) |
MX (1) | MX340055B (ja) |
MY (1) | MY175260A (ja) |
PL (1) | PL2419732T3 (ja) |
PT (1) | PT2419732T (ja) |
RS (1) | RS59896B1 (ja) |
RU (1) | RU2559570C2 (ja) |
SG (1) | SG175239A1 (ja) |
SI (1) | SI2419732T1 (ja) |
WO (1) | WO2010121000A1 (ja) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8137684B2 (en) * | 1996-10-01 | 2012-03-20 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
US20030199425A1 (en) * | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
ES2685436T3 (es) | 2002-12-09 | 2018-10-09 | Abraxis Bioscience, Llc | Composiciones y procedimientos para administración de agentes farmacológicos |
KR20140016402A (ko) | 2005-02-18 | 2014-02-07 | 아브락시스 바이오사이언스, 엘엘씨 | 치료제의 조합 및 투여 방식, 및 조합 요법 |
US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
SI1931321T1 (sl) | 2005-08-31 | 2019-07-31 | Abraxis Bioscience, Llc | Sestave, ki zajemajo slabo vodotopne farmacevtske učinkovine in antimikrobna sredstva |
ES2700074T3 (es) * | 2006-12-14 | 2019-02-13 | Abraxis Bioscience Llc | Terapia para el cáncer de mama sobre la base del estado de los receptores hormonales con nanopartículas que comprenden taxano |
UA118645C2 (uk) | 2007-03-07 | 2019-02-25 | Абраксіс Байосайєнс, Елелсі. | Спосіб комбінованої терапії раку наночастинками, що містять рапаміцин і альбумін |
EP2146707A2 (en) * | 2007-05-03 | 2010-01-27 | Abraxis BioScience, LLC | Methods and compositions for treating pulmonary hypertension |
US8927019B2 (en) | 2007-06-01 | 2015-01-06 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
MX2010011165A (es) * | 2008-04-10 | 2011-02-22 | Abraxis Bioscience Llc | Composiciones de derivados de taxano hidrofobos y sus usos. |
AU2010236382B2 (en) | 2009-04-15 | 2016-01-14 | Abraxis Bioscience, Llc | Prion-free nanoparticle compositions and methods |
AU2011230512B2 (en) | 2010-03-26 | 2016-09-15 | Abraxis Bioscience, Llc | Methods of treatment of hepatocellular carcinoma |
NZ703047A (en) | 2010-03-29 | 2016-11-25 | Abraxis Bioscience Llc | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
MX364637B (es) | 2010-03-29 | 2019-05-03 | Abraxis Bioscience Llc Star | Platino y nanopartículas que incluyen placlitaxel/albúmina para usarse en el trartamiento de nsclc. |
MY162903A (en) | 2010-06-04 | 2017-07-31 | Abraxis Bioscience Llc | Methods of treatment of pancreatic cancer |
WO2012129371A2 (en) * | 2011-03-22 | 2012-09-27 | Nant Holdings Ip, Llc | Reasoning engines |
CN103648521A (zh) | 2011-04-28 | 2014-03-19 | 阿布拉科斯生物科学有限公司 | 纳米颗粒组合物的血管内递送及其应用 |
EP2790675B1 (en) | 2011-12-14 | 2019-07-03 | Abraxis BioScience, LLC | Use of polymeric excipients for lyophilization or freezing of particles |
WO2013115559A1 (ko) * | 2012-01-30 | 2013-08-08 | 성균관대학교 산학협력단 | 수난용성 약물을 내부에 포함하는 알부민 나노입자 제조방법 |
US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
MX370662B (es) | 2013-03-12 | 2019-12-19 | Abraxis Bioscience Llc | Composiciones que comprenden nanopartículas de paclitaxel y albúmina para usarse en el tratamiento de cáncer. |
SG11201507234UA (en) | 2013-03-14 | 2015-10-29 | Abraxis Bioscience Llc | Methods of treating bladder cancer |
US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
DK3313401T3 (da) | 2015-06-29 | 2021-11-15 | Abraxis Bioscience Llc | Nanopartikler omfattende sirolimus og albumin til anvendelse i behandling af epithelioide celletumorer |
BR112020018910A2 (pt) | 2018-03-20 | 2020-12-29 | Abraxis Bioscience, Llc | Métodos de tratamento de transtorno do sistema nervoso central através da administração de nanopartículas de um unibidor de mtor e de uma albumina |
AU2020375810A1 (en) * | 2019-10-28 | 2022-05-12 | Abraxis Bioscience, Llc | Pharmaceutical compositions of albumin and rapamycin |
US20220347193A1 (en) * | 2021-04-28 | 2022-11-03 | New Jersey Institute Of Technology | Targeted Nanoparticle For The Treatment Of Traumatic Brain Injury And Other CNS Diseases |
Family Cites Families (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1256110B (it) * | 1992-11-23 | 1995-11-28 | Procedimento di coniugazione di nucleosidi antivirali con albumina umana lattosaminata | |
US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
US20070117862A1 (en) | 1993-02-22 | 2007-05-24 | Desai Neil P | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
US6528067B1 (en) | 1993-02-22 | 2003-03-04 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
US5665382A (en) | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of pharmaceutically active agents for in vivo delivery |
US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US5665383A (en) | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of immunostimulating agents for in vivo delivery |
US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US5650156A (en) | 1993-02-22 | 1997-07-22 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of nutriceuticals and compositions useful therefor |
EP0693924B2 (en) | 1993-02-22 | 2008-04-09 | Abraxis BioScience, Inc. | Methods for (in vivo) delivery of biologics and compositions useful therefor |
US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
US20030068362A1 (en) | 1993-02-22 | 2003-04-10 | American Bioscience, Inc. | Methods and formulations for the delivery of pharmacologically active agents |
US5997904A (en) | 1993-02-22 | 1999-12-07 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
US5362478A (en) | 1993-03-26 | 1994-11-08 | Vivorx Pharmaceuticals, Inc. | Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell |
JP2930421B2 (ja) * | 1994-02-28 | 1999-08-03 | メディノヴァ メディカル コンサルティング ゲゼルシャフト ミット ベシュレンクテル ハフツング | 薬剤組成物、その製造方法及びその使用方法 |
US6565842B1 (en) | 1995-06-07 | 2003-05-20 | American Bioscience, Inc. | Crosslinkable polypeptide compositions |
GB9519197D0 (en) | 1995-09-20 | 1995-11-22 | Affinity Chromatography Ltd | Novel affinity ligands and their use |
US5750361A (en) | 1995-11-02 | 1998-05-12 | The Regents Of The University Of California | Formation and use of prion protein (PRP) complexes |
US6537539B2 (en) | 1996-01-11 | 2003-03-25 | Human Genome Sciences, Inc. | Immune cell cytokine |
US8137684B2 (en) | 1996-10-01 | 2012-03-20 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
US6221614B1 (en) | 1997-02-21 | 2001-04-24 | The Regents Of The University Of California | Removal of prions from blood, plasma and other liquids |
US6719988B2 (en) * | 1997-02-21 | 2004-04-13 | The Regents Of The University Of California | Antiseptic compositions for inactivating prions |
CN100462066C (zh) | 1997-06-27 | 2009-02-18 | 美国生物科学有限公司 | 药剂的新制剂及其制备和应用方法 |
US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
US20030199425A1 (en) | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
US6150172A (en) | 1999-01-08 | 2000-11-21 | The United States Of America As Represented By The Secretary Of Agriculture | Method and kit for extracting prion protein |
WO2000064437A1 (en) | 1999-04-22 | 2000-11-02 | American Biosciences, Inc. | Long term administration of pharmacologically active agents |
EP1091877B1 (de) | 1999-04-30 | 2005-05-25 | Krones Ag | Verfahren und vorrichtung zum aufbringen von etikettenhülsen auf gegenstände |
AU784416B2 (en) | 1999-05-21 | 2006-03-30 | Abraxis Bioscience, Llc | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
ITMI20001107A1 (it) | 2000-05-18 | 2001-11-18 | Acs Dobfar Spa | Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel |
US7252799B2 (en) * | 2001-08-31 | 2007-08-07 | Clearant, Inc. | Methods for sterilizing preparations containing albumin |
ITMI20020680A1 (it) | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento |
ITMI20020681A1 (it) | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina |
ATE555666T1 (de) | 2002-05-23 | 2012-05-15 | Ortho Clinical Diagnostics Inc | Einfang, konzentration und quantifizierung eines abnormalen prionproteins aus biologischen flüssigkeiten mittels tiefenfiltration |
EP1520733B1 (en) | 2002-07-05 | 2009-10-28 | The Yokohama Rubber Co., Ltd. | Pneumatic tire for ice-bound or snow-covered road |
EP2317317B1 (en) * | 2002-12-03 | 2014-11-26 | North Carolina State University | Prion protein ligands and methods of use |
ES2685436T3 (es) * | 2002-12-09 | 2018-10-09 | Abraxis Bioscience, Llc | Composiciones y procedimientos para administración de agentes farmacológicos |
KR20150108943A (ko) | 2002-12-09 | 2015-09-30 | 아브락시스 바이오사이언스, 엘엘씨 | 약리학적 물질의 조성물 및 그 전달방법 |
SG187269A1 (en) | 2003-04-04 | 2013-02-28 | Univ North Carolina State | Prion protein binding materials and methods of use |
US7510848B2 (en) * | 2003-04-04 | 2009-03-31 | North Carolina State University | Prion protein binding materials and methods of use |
GB0416699D0 (en) * | 2004-07-27 | 2004-09-01 | Prometic Biosciences Ltd | Prion protein ligands and methods of use |
US20070166388A1 (en) | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
KR20140016402A (ko) | 2005-02-18 | 2014-02-07 | 아브락시스 바이오사이언스, 엘엘씨 | 치료제의 조합 및 투여 방식, 및 조합 요법 |
US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
ES2719093T3 (es) * | 2005-08-31 | 2019-07-08 | Abraxis Bioscience Llc | Composiciones de fármacos poco solubles en agua con mayor estabilidad y métodos para su preparación |
SI1931321T1 (sl) | 2005-08-31 | 2019-07-31 | Abraxis Bioscience, Llc | Sestave, ki zajemajo slabo vodotopne farmacevtske učinkovine in antimikrobna sredstva |
US20080280987A1 (en) | 2006-08-31 | 2008-11-13 | Desai Neil P | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
EP2056812A1 (en) | 2006-08-31 | 2009-05-13 | Abraxis BioScience, LLC | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
US20100112077A1 (en) | 2006-11-06 | 2010-05-06 | Abraxis Bioscience, Llc | Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer |
ES2700074T3 (es) | 2006-12-14 | 2019-02-13 | Abraxis Bioscience Llc | Terapia para el cáncer de mama sobre la base del estado de los receptores hormonales con nanopartículas que comprenden taxano |
UA118645C2 (uk) | 2007-03-07 | 2019-02-25 | Абраксіс Байосайєнс, Елелсі. | Спосіб комбінованої терапії раку наночастинками, що містять рапаміцин і альбумін |
EP2146707A2 (en) | 2007-05-03 | 2010-01-27 | Abraxis BioScience, LLC | Methods and compositions for treating pulmonary hypertension |
US8927019B2 (en) | 2007-06-01 | 2015-01-06 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
MX2010011165A (es) | 2008-04-10 | 2011-02-22 | Abraxis Bioscience Llc | Composiciones de derivados de taxano hidrofobos y sus usos. |
KR20150136137A (ko) | 2008-04-10 | 2015-12-04 | 아브락시스 바이오사이언스, 엘엘씨 | 소수성 탁산 유도체의 조성물 및 그의 용도 |
CA2746129A1 (en) | 2008-12-11 | 2010-06-17 | Abraxis Bioscience, Llc | Combination chemotherapy of nanoparticulate taxanes and inhibitors of pro-survival and/or inflammatory signals |
NZ595189A (en) | 2009-03-13 | 2013-08-30 | Abraxis Bioscience Llc | Combination therapy with thiocolchicine derivatives |
AU2010233097B2 (en) | 2009-04-10 | 2016-04-07 | Abraxis Bioscience, Llc | Nanoparticle formulations and uses thereof |
AU2010236382B2 (en) * | 2009-04-15 | 2016-01-14 | Abraxis Bioscience, Llc | Prion-free nanoparticle compositions and methods |
PT2470173E (pt) | 2009-08-25 | 2016-06-15 | Abraxis Bioscience Llc | Terapia de combinação com composições nanoparticuladas de taxano e inibidores hedgehog |
AU2011230512B2 (en) | 2010-03-26 | 2016-09-15 | Abraxis Bioscience, Llc | Methods of treatment of hepatocellular carcinoma |
MX364637B (es) * | 2010-03-29 | 2019-05-03 | Abraxis Bioscience Llc Star | Platino y nanopartículas que incluyen placlitaxel/albúmina para usarse en el trartamiento de nsclc. |
NZ703047A (en) | 2010-03-29 | 2016-11-25 | Abraxis Bioscience Llc | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
MX343671B (es) | 2010-06-02 | 2016-11-16 | Abraxis Bioscience Llc * | Metodos de tratamiento de cancer de vejiga. |
MY162903A (en) | 2010-06-04 | 2017-07-31 | Abraxis Bioscience Llc | Methods of treatment of pancreatic cancer |
EP3056201A1 (en) | 2010-06-07 | 2016-08-17 | Abraxis BioScience, LLC | Combination therapy methods for treating proliferative diseases |
CN103648521A (zh) | 2011-04-28 | 2014-03-19 | 阿布拉科斯生物科学有限公司 | 纳米颗粒组合物的血管内递送及其应用 |
EP2790675B1 (en) | 2011-12-14 | 2019-07-03 | Abraxis BioScience, LLC | Use of polymeric excipients for lyophilization or freezing of particles |
US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
US20140186447A1 (en) | 2012-12-28 | 2014-07-03 | Abraxis Bioscience, Llc | Nanoparticle compositions of albumin and paclitaxel |
US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
US20140199405A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on mutation status of k-ras |
US20140199404A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on level of a nucleoside transporter |
MX370662B (es) | 2013-03-12 | 2019-12-19 | Abraxis Bioscience Llc | Composiciones que comprenden nanopartículas de paclitaxel y albúmina para usarse en el tratamiento de cáncer. |
US20160015817A1 (en) | 2013-03-13 | 2016-01-21 | Abraxis Bioscience, Llc | Methods of treatment of pediatric solid tumor |
SG11201507234UA (en) | 2013-03-14 | 2015-10-29 | Abraxis Bioscience Llc | Methods of treating bladder cancer |
WO2015157120A1 (en) | 2014-04-06 | 2015-10-15 | Abraxis Bioscience, Llc | Combination therapy comprising nanoparticles of a taxane and albumin with abt-263 in methods for treating cancer |
WO2016141365A1 (en) | 2015-03-05 | 2016-09-09 | Abraxis Bioscience, Llc | Method for treating cancer based on level of glucocorticoid receptor |
CA2990703C (en) | 2015-06-29 | 2024-04-30 | Abraxis Bioscience, Llc | Biomarkers for nanoparticle compositions |
AU2016287508B2 (en) | 2015-06-29 | 2021-10-14 | Abraxis Bioscience, Llc | Methods of treating solid tumors using nanoparticle MTOR inhibitor combination therapy |
DK3313401T3 (da) | 2015-06-29 | 2021-11-15 | Abraxis Bioscience Llc | Nanopartikler omfattende sirolimus og albumin til anvendelse i behandling af epithelioide celletumorer |
US20170181988A1 (en) | 2015-12-23 | 2017-06-29 | Cipla Limited | Methods for the treatment of bladder cancer |
-
2010
- 2010-04-15 AU AU2010236382A patent/AU2010236382B2/en active Active
- 2010-04-15 SG SG2011075264A patent/SG175239A1/en unknown
- 2010-04-15 RS RS20191601A patent/RS59896B1/sr unknown
- 2010-04-15 PL PL10765167T patent/PL2419732T3/pl unknown
- 2010-04-15 EP EP19192486.9A patent/EP3626233A1/en not_active Withdrawn
- 2010-04-15 ME MEP-2019-364A patent/ME03596B/me unknown
- 2010-04-15 RU RU2011146132/15A patent/RU2559570C2/ru active
- 2010-04-15 JP JP2012506210A patent/JP5781500B2/ja active Active
- 2010-04-15 KR KR1020117027031A patent/KR20120044279A/ko not_active Application Discontinuation
- 2010-04-15 HU HUE10765167A patent/HUE047376T2/hu unknown
- 2010-04-15 CN CN201080026604.3A patent/CN102460167B/zh active Active
- 2010-04-15 LT LTEP10765167.1T patent/LT2419732T/lt unknown
- 2010-04-15 BR BRPI1012525-6A patent/BRPI1012525A2/pt not_active Application Discontinuation
- 2010-04-15 US US12/761,292 patent/US20100297243A1/en not_active Abandoned
- 2010-04-15 EP EP10765167.1A patent/EP2419732B1/en active Active
- 2010-04-15 PT PT107651671T patent/PT2419732T/pt unknown
- 2010-04-15 WO PCT/US2010/031197 patent/WO2010121000A1/en active Application Filing
- 2010-04-15 DK DK10765167.1T patent/DK2419732T3/da active
- 2010-04-15 SI SI201031963T patent/SI2419732T1/sl unknown
- 2010-04-15 MY MYPI2011004956A patent/MY175260A/en unknown
- 2010-04-15 MX MX2011010825A patent/MX340055B/es active IP Right Grant
- 2010-04-15 ES ES10765167T patent/ES2764100T3/es active Active
- 2010-04-15 CA CA2758913A patent/CA2758913A1/en not_active Abandoned
-
2011
- 2011-10-23 IL IL215765A patent/IL215765A/en active IP Right Grant
-
2014
- 2014-02-26 US US14/191,279 patent/US9446003B2/en active Active
-
2015
- 2015-04-24 JP JP2015089364A patent/JP6433371B2/ja active Active
-
2016
- 2016-08-17 US US15/239,680 patent/US10206887B2/en active Active
- 2016-11-24 JP JP2016227715A patent/JP2017061537A/ja active Pending
-
2019
- 2019-12-11 CY CY20191101294T patent/CY1122617T1/el unknown
- 2019-12-16 HR HRP20192259TT patent/HRP20192259T1/hr unknown
Non-Patent Citations (1)
Title |
---|
BARLETTA JM., et al., Detection of ultra-low levels of pathologic prion protein in scrapie infected hamster brain homogenates using real-time immuno-PCR. J Virol Methods. 2005 Aug;127(2):154-64 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2559570C2 (ru) | Композиции без приона на основе наночастиц и способы их получения | |
Fan et al. | Curcumin-loaded PLGA-PEG nanoparticles conjugated with B6 peptide for potential use in Alzheimer’s disease | |
Hannon et al. | Immunotoxicity considerations for next generation cancer nanomedicines | |
Zheng et al. | Plasma exosomes spread and cluster around β-amyloid plaques in an animal model of Alzheimer’s disease | |
RU2749732C2 (ru) | Препараты антител | |
JP5793076B2 (ja) | 血液由来インター−アルファ−阻害タンパク質の調製及び組成物。 | |
Lin et al. | Effect of poly (amidoamine) dendrimers on the structure and activity of immune molecules | |
Kempuraj et al. | Glia maturation factor and mast cell-dependent expression of inflammatory mediators and proteinase activated receptor-2 in neuroinflammation | |
ES2324334T3 (es) | Productos terapeuticos para las celulas t para la encefalopatia espongiforme transmisible y metodo para la fabricacion de productos derivados de tejidos y fluidos corporales no infecciosos. | |
ZA200500062B (en) | Proteins binding to cross-beta structure comprising amyloid and methods for detection and modulationof the cross-beta structure, its formation and it s associated toxicity. | |
US20140249087A1 (en) | Use of hemopexin to sequester hemoglobin | |
Jin et al. | High-density lipoprotein in Alzheimer's disease: From potential biomarkers to therapeutics | |
Ortega et al. | Reframing the link between metabolism and NLRP3 inflammasome: therapeutic opportunities | |
Dang et al. | Efficacy of local delivery of ardipusilloside I using biodegradable implants against cerebral tumor growth | |
JP5201988B2 (ja) | プリオン蛋白質リガンドとしての置換トリアジン、及び、プリオンを検出又は除去するための該置換トリアジンの使用 | |
Zhen et al. | β-amyloid peptide 1–42-conjugated magnetic nanoparticles for the isolation and purification of glycoproteins in egg white | |
Gao et al. | Proline-Loaded Chitosan Nanoparticles Penetrate the Blood–Brain Barrier to Confer Neuroprotection in Mice Cerebral Ischemia Injury | |
Liu et al. | Neurotoxic Effect of the Complex of the Ovine Prion Protein (OvPrP C) and RNA on the Cultured Rat Cortical Neurons | |
Pikwong | Development of gelatine-covered silica nanoparticles for delivering recombinant human secretory leukocyte protease inhibitor (rhslpi) for reducing myocardial ischaemia/reperfusion injury | |
Chacko et al. | Nano-Theranostics approaches and Mitochondrial Targeted Drug Delivery: Alzheimer’s disease therapeutic interventions | |
Ai Tran | Therapeutic approaches for prion diseases and related neurogenerative disorders |